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March 4, 2008:968–73TWA value as positive. Although this analysis operates on this
ichotomy to generate the “positive” and the “negative” response of
patient to MTWA testing, thus creating a qualitative context,
here is a quantitative issue as its underpinning (i.e., a patient has
o reach the threshold to qualify as “positive”). Moreover, current
ork indicates that the magnitude in V of MTWA may be of
mportance, and higher values of calculated MTWA may imply
orse prognosis (3,4), or therapy with various drugs, particularly
eta-blockers, may attenuate the magnitude of MTWA (5).
owever, more work is needed to substantiate the claim that the
uantitative assessment of MTWA may have advantages over the
ualitative evaluation. In the meantime, it is important to deal with
ome possible confounders of the quantitative employment of the
TWA, 1 of which may be its T-wave amplitude dependence (6).
ccordingly, in the presence of ventricular conduction delays,
hich often are associated with T waves larger in amplitude than
he ones encountered in association with normal intraventricular
onduction, a greater magnitude of MTWA in the former than in
he latter may not mean a higher risk for sudden cardiac death or
alignant ventricular arrhythmia, but merely an enhancing effect
f the taller T waves on the magnitude of MTWA in patients with
ide QRS complexes. Probably this was the reason for the
ncreased rate of false-positive MTWA tests in patients with wide
RS complexes (120 ms) (specificity 22% in the patients with a
ide QRS and 40% in the patients with a narrow QRS) in the
uthors’ other report (2). In that report they categorized their
atients to those with QRS duration of 120 ms and 120 ms
2). In their present contribution (1), by employing 3 categories of
atients in terms of QRS duration (Table 1) (QRS110 ms, QRS
10 ms to 120 ms, and QRS 120 ms), they provide an
pportunity to evaluate the effect of the amplitude of the T waves
n the magnitude of MTWA in a “dose response” fashion. What
s needed for this is a comparison of the values of MTWA in V,
nd the T-wave amplitudes in mV in the above 3 categories of
atients, according to their QRS duration. Could the authors
rovide us with these data? Evaluation of possible determinants of
he MTWA and potential adjustment via a MTWA index (6) may
pgrade both the currently used “qualitative” assessment and a
uture adoption of quantitative assessment of MTWA testing.
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ercutaneous
ntervention in Saphenous
ein Bypass Graft Disease
ase Against the Use
f Drug-Eluting Stents
aphenous vein grafts (SVGs) tend to degenerate over time, and
lmost one-half develop significant stenosis and nearly 40% are
ompletely occluded within 1 decade (1). Use of balloon angio-
lasty alone without stenting for treatment of SVG disease is
ssociated with poor short-term and long-term outcome (2). Use
f bare-metal stents (BMS) is associated with restenosis rates as
igh as 50% at 6 months (3). Lately, drug-eluting stents (DES)
ave been used for the treatment of SVG disease.
In contrast to the native coronary arteries, in which restenosis after
ercutaneous coronary intervention (PCI) is mainly due to intimal
yperplasia, restenosis in SVG involves cellular hyperplasia, progres-
ion of atherosclerosis, local inflammatory reaction to stent struts, and
hrombosis. These observations suggest that it may not be wise to
xtend the seemingly better short- and midterm results seen with PCI
or treatment of native coronary artery disease to the treatment of
VG disease.We have recently looked at the data in our institution in
09 patients with SVG disease who received BMS or DES. During
follow-up period of 33 months, we found that the incidence of
Figure 1 Kaplan-Meier Survival Curves for
Freedom From MACE at Almost 3 Years Follow-Up
BMS  bare-metal stents; DES  drug-eluting
stents; MACE  major adverse cardiac events.
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March 4, 2008:968–73ajor adverse cardiac events (MACE) was much higher in patients
reated with DES.We found that there was initially a benefit in terms
f MACE in patients who received DES compared with the benefit
een in patients receiving BMS, but thereafter we noticed a late
atch-up phenomenon (Fig. 1).
In this regard, Chu et al. (4) in a small study showed that
lthough there were no differences in DES and BMS used for the
reatment of SVG disease, the incidence of MACE increased from
months to 1 year after PCI in the BMS group, and the DES
roup had a much more pronounced increase in MACE in the
ame time frame. The secondary post-hoc data from the delayed
RISC (Reduction of Restenosis In Saphenous vein grafts with
ypher Stent) trial (5) also showed that over a median follow-up
f 32 months, use of BMS was associated with significantly lower
ong-term mortality than the use of DES in SVG disease. The use
f DES in the SVG disease needs to be re-examined.
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eply
e really welcome the additional data provided by Dr. Bansal and
olleagues over the mid- and long-term outcome of drug-eluting
tents (DES) in diseased saphenous vein grafts (SVGs). We also
ppreciate the words of caution expressed by the authors and
ocused on a more careful use of DES in this type of lesion. Indeed,
heir data, as well as our long-term data from the DELAYED
RISC (Death and Events at Long-term follow-up AnalYsis:
xtended Duration of the Reduction of Restenosis In Saphenous
ein grafts with Cypher stent) trial (1), and the data from Chu
t al. (2), all point out that in the long term DES seem not to
aintain the possible advantages shown in the midterm. Another
dditional study (a sub-study of the large prospective STENT
Strategic Transcatheter Evaluation of New Therapies] registry),ecently presented as an abstract, also showed no differences
etween DES and bare-metal stents in SVGs (3). To our knowl-
dge, while there are some data showing benefit of DES over
are-metal stents in the midterm (up to 6 to 9 months), there are
o registries showing the same benefit in the long term (1 year).
he only long-term study is the one previously mentioned, and all
how a similar trend without clear advantage of DES over
are-metal stents.
However, we have to underline some issues related to all these
nalyses. On the one hand, our data are focused only on sirolimus-
luting stents and not on other types of DES (1). On the other
and, the data of Dr. Bansal and colleagues, of Chu et al. (2), and
f the STENT registry (3) were based on analyses encompassing
ifferent types of DES. Whether their results were mainly driven
y a suboptimal performance of one type of DES over the others
r whether there is a “class-effect” of DES in SVG, this cannot be
vinced by the data provided. New prospective studies are under-
oing in order to also offer additional data on other types of DES,
uch as polymeric paclitaxel-eluting stents (4). In addition, as all of
hese studies analyzed de-novo lesions in SVGs, we have a total
ack of data on the way DES perform in restenotic SVG lesions.
While waiting for a conclusive large and well-powered random-
zed trial of DES versus bare-metal stents in SVGs, in our opinion
he use of DES in this lesion subset in daily life clinical practice
hould be discouraged (unless prospectively evaluated in a study).
f there is a willingness to implant a DES in a diseased SVG, this
hould be firmly discussed with the patient, and a careful assess-
ent of the possible advantages and risks related to the implan-
ation of this device should be cautiously evaluated. Moreover, we
elcome interventional cardiologists that implanted DES in SVGs
o try to collect long-term data on their patients in order to provide
dditional data to the scientific community, like Dr. Bansal et al.
emarkably did in their letter.
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